Does the media favor CORT or MBX?

In the previous week, Corcept Therapeutics had 26 more articles in the media than MBX Biosciences. MarketBeat recorded 31 mentions for Corcept Therapeutics and 5 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.25 beat Corcept Therapeutics' score of 0.77 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive MBX Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELAN or MBX?

In the previous week, Elanco Animal Health had 11 more articles in the media than MBX Biosciences. MarketBeat recorded 16 mentions for Elanco Animal Health and 5 mentions for MBX Biosciences. Elanco Animal Health's average media sentiment score of 1.60 beat MBX Biosciences' score of 1.25 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MBX Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AXSM or MBX?

In the previous week, Axsome Therapeutics had 8 more articles in the media than MBX Biosciences. MarketBeat recorded 13 mentions for Axsome Therapeutics and 5 mentions for MBX Biosciences. Axsome Therapeutics' average media sentiment score of 1.55 beat MBX Biosciences' score of 1.25 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MBX Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend RDY or MBX?

MBX Biosciences has a consensus price target of $77.00, suggesting a potential upside of 16.09%. Given MBX Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe MBX Biosciences is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 MBX Biosciences 2 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.77

Does the media prefer RDY or MBX?

In the previous week, MBX Biosciences had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 5 mentions for MBX Biosciences and 2 mentions for Dr. Reddy's Laboratories. MBX Biosciences' average media sentiment score of 1.25 beat Dr. Reddy's Laboratories' score of -0.73 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative MBX Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MBX or CRNX?

In the previous week, MBX Biosciences had 1 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 5 mentions for MBX Biosciences and 4 mentions for Crinetics Pharmaceuticals. MBX Biosciences' average media sentiment score of 1.25 beat Crinetics Pharmaceuticals' score of 1.14 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MBX Biosciences (MBX) Competitors

$66.33 -0.02 (-0.03%)

As of 08/21/2026 04:00 PM Eastern

Compare

MBX vs. CORT, ELAN, AXSM, RDY, and CRNX

Should you buy MBX Biosciences stock or one of its competitors? MBX Biosciences's main competitors and comparable companies include Corcept Therapeutics (CORT), Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), and Crinetics Pharmaceuticals (CRNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MBX Biosciences compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Corcept Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

Corcept Therapeutics has a net margin of 6.52% compared to MBX Biosciences' net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
MBX Biosciences	N/A	-26.02%	-24.94%

93.6% of Corcept Therapeutics shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by insiders. Comparatively, 31.1% of MBX Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Corcept Therapeutics has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$830.81M	15.91	$99.65M	$0.42	291.07
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

In the previous week, Corcept Therapeutics had 26 more articles in the media than MBX Biosciences. MarketBeat recorded 31 mentions for Corcept Therapeutics and 5 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.25 beat Corcept Therapeutics' score of 0.77 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
MBX Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corcept Therapeutics currently has a consensus price target of $138.17, suggesting a potential upside of 13.02%. MBX Biosciences has a consensus price target of $77.00, suggesting a potential upside of 16.09%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe MBX Biosciences is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

Corcept Therapeutics beats MBX Biosciences on 10 of the 16 factors compared between the two stocks.

How does MBX Biosciences compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

97.5% of Elanco Animal Health shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by insiders. Comparatively, 31.1% of MBX Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MBX Biosciences has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
MBX Biosciences	N/A	-26.02%	-24.94%

Elanco Animal Health presently has a consensus price target of $29.09, suggesting a potential upside of 20.96%. MBX Biosciences has a consensus price target of $77.00, suggesting a potential upside of 16.09%. Given Elanco Animal Health's higher probable upside, equities research analysts clearly believe Elanco Animal Health is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

MBX Biosciences has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.55	-$232M	-$0.41	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

Elanco Animal Health has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

In the previous week, Elanco Animal Health had 11 more articles in the media than MBX Biosciences. MarketBeat recorded 16 mentions for Elanco Animal Health and 5 mentions for MBX Biosciences. Elanco Animal Health's average media sentiment score of 1.60 beat MBX Biosciences' score of 1.25 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MBX Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Elanco Animal Health beats MBX Biosciences on 9 of the 14 factors compared between the two stocks.

How does MBX Biosciences compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

In the previous week, Axsome Therapeutics had 8 more articles in the media than MBX Biosciences. MarketBeat recorded 13 mentions for Axsome Therapeutics and 5 mentions for MBX Biosciences. Axsome Therapeutics' average media sentiment score of 1.55 beat MBX Biosciences' score of 1.25 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	11 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MBX Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics currently has a consensus target price of $267.60, suggesting a potential upside of 28.80%. MBX Biosciences has a consensus target price of $77.00, suggesting a potential upside of 16.09%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Axsome Therapeutics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Axsome Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

81.5% of Axsome Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 31.1% of MBX Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MBX Biosciences has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -24.68%. MBX Biosciences' return on equity of -26.02% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
MBX Biosciences	N/A	-26.02%	-24.94%

MBX Biosciences has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.04	-$183.17M	-$3.75	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

Summary

Axsome Therapeutics beats MBX Biosciences on 9 of the 16 factors compared between the two stocks.

How does MBX Biosciences compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to MBX Biosciences' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
MBX Biosciences	N/A	-26.02%	-24.94%

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 31.1% of MBX Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.84	$456M	$0.44	27.70
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

In the previous week, MBX Biosciences had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 5 mentions for MBX Biosciences and 2 mentions for Dr. Reddy's Laboratories. MBX Biosciences' average media sentiment score of 1.25 beat Dr. Reddy's Laboratories' score of -0.73 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
MBX Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences has a consensus price target of $77.00, suggesting a potential upside of 16.09%. Given MBX Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe MBX Biosciences is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Dr. Reddy's Laboratories has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

Summary

Dr. Reddy's Laboratories beats MBX Biosciences on 9 of the 16 factors compared between the two stocks.

How does MBX Biosciences compare to Crinetics Pharmaceuticals?

MBX Biosciences (NASDAQ:MBX) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

MBX Biosciences has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. MBX Biosciences' return on equity of -26.02% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

MBX Biosciences has higher earnings, but lower revenue than Crinetics Pharmaceuticals. MBX Biosciences is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Crinetics Pharmaceuticals	$7.70M	1,166.63	-$465.32M	-$5.04	N/A

In the previous week, MBX Biosciences had 1 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 5 mentions for MBX Biosciences and 4 mentions for Crinetics Pharmaceuticals. MBX Biosciences' average media sentiment score of 1.25 beat Crinetics Pharmaceuticals' score of 1.14 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market.

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MBX Biosciences presently has a consensus target price of $77.00, indicating a potential upside of 16.09%. Crinetics Pharmaceuticals has a consensus target price of $81.00, indicating a potential downside of 4.36%. Given MBX Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe MBX Biosciences is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Summary

MBX Biosciences beats Crinetics Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get MBX Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBX vs. The Competition

Export

Metric	MBX Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.19B	$12.57B	$7.37B	$12.85B
Dividend Yield	N/A	2.61%	2.53%	11.08%
P/E Ratio	-27.52	789.80	272.60	24.24
Price / Sales	N/A	764.50	618.96	99.78
Price / Cash	N/A	96.77	78.62	53.99
Price / Book	7.80	11.89	13.05	6.20
Net Income	-$86.97M	$2.81B	$3.47B	$348.59M
7 Day Performance	-3.27%	1.77%	2.09%	0.08%
1 Month Performance	4.34%	3.85%	6.64%	3.88%
1 Year Performance	N/A	6.56%	25.02%	16.98%

MBX Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBX MBX Biosciences	2.9855 of 5 stars	$66.33 0.0%	$77.00 +16.1%	N/A	$3.19B	N/A	N/A	N/A	News Coverage Positive News Analyst Forecast Gap Up
CORT Corcept Therapeutics	3.4681 of 5 stars	$114.47 +3.6%	$119.17 +4.1%	+73.8%	$12.37B	$761.41M	272.55	300	Trending News Analyst Forecast Insider Trade Analyst Revision
ELAN Elanco Animal Health	4.312 of 5 stars	$23.64 +5.0%	$29.09 +23.1%	+34.4%	$11.83B	$4.72B	N/A	9,400	Positive News Analyst Downgrade Insider Trade
AXSM Axsome Therapeutics	3.6758 of 5 stars	$213.67 0.0%	$267.60 +25.2%	+75.3%	$11.19B	$638.50M	N/A	380	Positive News Analyst Upgrade
RDY Dr. Reddy's Laboratories	1.8344 of 5 stars	$12.30 -1.0%	N/A	-16.0%	$10.24B	$3.58B	27.94	27,527

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MBX Biosciences (MBX) Competitors

MBX vs. CORT, ELAN, AXSM, RDY, and CRNX

How does MBX Biosciences compare to Corcept Therapeutics?

Summary

How does MBX Biosciences compare to Elanco Animal Health?

Summary

How does MBX Biosciences compare to Axsome Therapeutics?

Summary

How does MBX Biosciences compare to Dr. Reddy's Laboratories?

Summary

How does MBX Biosciences compare to Crinetics Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX vs. The Competition

MBX Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MBX Biosciences (MBX) Competitors

MBX vs. CORT, ELAN, AXSM, RDY, and CRNX

How does MBX Biosciences compare to Corcept Therapeutics?

Which has more risk and volatility, CORT or MBX?

Is CORT or MBX more profitable?

Do insiders and institutionals hold more shares of CORT or MBX?

Which has better valuation & earnings, CORT or MBX?

Does the media favor CORT or MBX?

Do analysts rate CORT or MBX?

Summary

How does MBX Biosciences compare to Elanco Animal Health?

Do institutionals and insiders have more ownership in ELAN or MBX?

Is ELAN or MBX more profitable?

Do analysts recommend ELAN or MBX?

Which has higher earnings and valuation, ELAN or MBX?

Which has more risk and volatility, ELAN or MBX?

Does the media prefer ELAN or MBX?

Summary

How does MBX Biosciences compare to Axsome Therapeutics?

Does the media prefer AXSM or MBX?

Do analysts recommend AXSM or MBX?

Which has more volatility and risk, AXSM or MBX?

Do institutionals & insiders have more ownership in AXSM or MBX?

Is AXSM or MBX more profitable?

Which has preferable earnings & valuation, AXSM or MBX?

Summary

How does MBX Biosciences compare to Dr. Reddy's Laboratories?

Is RDY or MBX more profitable?

Do insiders and institutionals have more ownership in RDY or MBX?

Which has better earnings and valuation, RDY or MBX?

Does the media prefer RDY or MBX?

Do analysts recommend RDY or MBX?

Which has more risk and volatility, RDY or MBX?

Summary

How does MBX Biosciences compare to Crinetics Pharmaceuticals?

Is MBX or CRNX more profitable?

Which has better earnings & valuation, MBX or CRNX?

Does the media favor MBX or CRNX?

Which has more risk and volatility, MBX or CRNX?

Do institutionals & insiders believe in MBX or CRNX?

Do analysts prefer MBX or CRNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX vs. The Competition

MBX Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools